C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2665728
Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.
L'invention concerne des compositions et des procédés pour traiter des maladies associées à CD20 : lymphomes, maladies auto-immunes et rejets de greffon. Lesdites compositions comprennent des anticorps anti-CD20 pouvant se lier à un antigène CD20 humain situé sur la surface d'une cellule d'expression de CD20 humaine, dans lequel l'anticorps à une cytotoxicité à médiation cellulaire dépend d'un complément accru (CDC) obtenu en plaçant au moins une CDR optimisée dans la zone variable de l'anticorps. Des compositions comprennent également des fragments de liaison à un antigène, des variantes et des dérivés des anticorps monoclonaux, des lignées cellulaires produisant ces compositions d'anticorps, et des molécules d'acide nucléique isolées codant les séquences d'acides aminés des anticorps. L'invention comprend en outre des compositions pharmaceutiques incluant les anticorps anti-CD20 de l'invention, ou des fragments de liaison à un antigène, des variantes ou des dérivés de ceux-ci, contenus dans un support pharmaceutiquement acceptable, et des procédés d'utilisation desdits anticorps anti-CD20.
Fisher Terrence L. Jr.
Smith Ernest S.
Smart & Biggar
Vaccinex Inc.
LandOfFree
Anti-cd20 antibodies and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cd20 antibodies and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cd20 antibodies and methods of use will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2017774